

PRODUCT SPECIFICATION

STATENS
SERUM
INSTITUT



HYB 345-02 Anti Cholecystokinin 26-33 (CCK-8)

Mouse monoclonal antibody

Article No.	63157 (0.2 mL), 101091 (1.0 mL)																
Product Name	HYB 345-02 Anti Cholecystokinin 26-33 (CCK-8)																
Clone	27F3..0,5D10																
Subclass	IgG2b / Kappa																
Description	Preparation:	Protein-A purified															
	Concentration:	1 mg/mL \pm 10%, based on A ₂₈₀ . See Certificate of Analysis for details.															
	Solvent:	PBS, pH 7.2 – 7.4															
	Storage:	-18 °C or colder															
Antigen	<p>Cholecystokinin fragment 26-33 (CCK-8) with sulfated Tyr²⁷. Cholecystokinin (1) plays a key role in facilitating digestion within the small intestine. It is secreted from mucosal epithelial cells in the first segment of the small intestine (duodenum). Cholecystokinin stimulates delivery into the small intestine of digestive enzymes from the pancreas and bile from the gallbladder. Cholecystokinin is also produced by neurons in the enteric nervous system, and is widely and abundantly distributed in the brain.</p> <p>Cholecystokinin is a linear peptide that is synthesized as a preprohormone, which is proteolytically cleaved to generate a family of peptides having the same carboxy ends. In all of these CCK peptides, the tyrosine 7 residue from the end is sulfated, which is necessary for activity. One of these peptides is the octa-peptide CCK-8 retaining full biologic activity.</p>																
Immunogen	CCK-12 coupled to carrier..																
Specificity	HYB 345-02 reacts with CCK-8 and the other CCK analogs with identical C-terminal ends as well as Gastrin II. No reactivity was observed with human heparin cofactor II.																
Epitope Specificity	Not determined.																
Reactivity	<p>HYB 345-02 is well suited for ELISA based measuring of CCK-8. We recommend coating with CCK-8 and using the antibody in a competitive assay protocol. Increased reactivity with sulphated CCK-8 compared to non-sulphated CCK-8 has been observed</p> <p>Immunofluorescence staining of bound HYB 345-02 can be used for identification of the subcellular distribution of CCK-8 in brain tissue (2-3).</p>																
Culture Medium	Dulbecco's modified Eagle's medium with 10% fetal calf serum.																
Fusion Partner	X63-Ag8.653.																
Immunization	Female NMRI mice were immunized i.p. with immunogen.																
Application	<table><thead><tr><th>Method</th><th>Usability</th><th>References</th></tr></thead><tbody><tr><td>ELISA</td><td>yes</td><td></td></tr><tr><td>Immunoblotting</td><td>nd.</td><td></td></tr><tr><td>Immunofluorescence</td><td>yes.</td><td>2-3</td></tr><tr><td>Immunochemistry</td><td>yes</td><td>2-3</td></tr></tbody></table>	Method	Usability	References	ELISA	yes		Immunoblotting	nd.		Immunofluorescence	yes.	2-3	Immunochemistry	yes	2-3	
Method	Usability	References															
ELISA	yes																
Immunoblotting	nd.																
Immunofluorescence	yes.	2-3															
Immunochemistry	yes	2-3															

HYB 345-02 Anti CCK-8

mouse monoclonal antibody

STATENS
SERUM
INSTITUT



References

- 1) **Rehfeld, J.F.** (2004). Clinical endocrinology and metabolism. Cholecystokinin. *Best Pract Res Clin Endocrinol Metab.*18, 569-586.
- 2) **Thibault K.** (2013). Activation-dependent subcellular distribution patterns of CB1 cannabinoid receptors in the rat forebrain. *Cereb. Cotex.* 23, 2581-2591.
- 3) **Iijima T, Iijima Y, Witte H, Scheiffle P.** Neuronal cell type-specific alternative splicing is regulated by the KH domain protein SLM1. *J Cell Biol.* 2014 Feb 3;204(3):331-42

Conditions

For research use only. Not for use in diagnostic procedures. Not for therapeutic use or applications.

The information and product are offered without guarantee as the ultimate conditions of use are beyond our control. The foregoing is in lieu of all warranties, expressed or implied, including implied warranties of merchantability and fitness for a particular purpose. In no event shall Statens Serum Institut be responsible for loss of profits or indirect consequential losses resulting from use of its products. The animals from which this product was derived have not been exposed to or inoculated with any livestock or poultry disease agents exotic to the United States or Western Europe, and did not originate from facilities where work with exotic disease agents affecting livestock or avian species is carried out.